Literature DB >> 26581586

Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.

Giuseppe Santabarbara1, Paolo Maione1, Antonio Rossi1, Cesare Gridelli1.   

Abstract

INTRODUCTION: Cisplatin is widely used in the treatment of several tumors such as lung, ovarian and testicular cancer with different degrees of effectiveness, and its use is burdened by some side effects. AREAS COVERED: This review includes the most important cisplatin side effects such as neurotoxicity, nephrotoxicity, ototoxicity, nausea and vomiting. They can affect patient's quality of life and lead to treatment interruptions with effectiveness reduction. EXPERT OPINION: Specific mechanisms of cisplatin-induced DNA damage and production of reactive oxygen species are the main ones responsible of toxicity. Several clinical approaches have been developed to reduce or prevent these effects with very promising results. The greatest potential for clinical practice is for amifostine, vitamin E, silymarin and NK-1 receptor antagonists.

Entities:  

Keywords:  Cisplatin; nausea; nephrotoxicity; neurotoxicity; ototoxicity; vomiting

Mesh:

Substances:

Year:  2015        PMID: 26581586     DOI: 10.1517/14656566.2016.1122757

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  11 in total

Review 1.  The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.

Authors:  Giuseppe Santabarbara; Paolo Maione; Antonio Rossi; Giovanni Palazzolo; Cesare Gridelli
Journal:  Ann Transl Med       Date:  2016-06

Review 2.  DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?

Authors:  Nuno Tiago Tavares; Saulė Gumauskaitė; João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

3.  Cisplatin-Induced Reproductive Toxicity and Oxidative Stress: Ameliorative Effect of Kinetin.

Authors:  Rania Abdel-Latif; Moustafa Fathy; Hend Ali Anwar; Muhammad Naseem; Thomas Dandekar; Eman M Othman
Journal:  Antioxidants (Basel)       Date:  2022-04-28

4.  Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4'-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2'-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers.

Authors:  Tzu-Chun Kan; Mei-Hsiang Lin; Chun-Chia Cheng; Jeng-Wei Lu; Ming-Thau Sheu; Yuan-Soon Ho; Sri Rahayu; Jungshan Chang
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

5.  Potential Combinational Anti-Cancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin.

Authors:  Chia-Yi Tseng; Chin-Hung Lin; Lung-Yuan Wu; Jhih-Syuan Wang; Meng-Chi Chung; Jing-Fen Chang; Ming-Wei Chao
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

6.  Cost analysis of adverse events associated with non-small cell lung cancer management in France.

Authors:  Christos Chouaid; Delphine Loirat; Emilie Clay; Aurélie Millier; Chloé Godard; Amira Fannan; Laurie Lévy-Bachelot; Eric Angevin
Journal:  Clinicoecon Outcomes Res       Date:  2017-07-27

7.  Complete Remission of Locally Advanced Penile Squamous Cell Carcinoma after Multimodality Treatment.

Authors:  Yifan Meng; Helen Levey Bernie; Tzu-Hua Weng; Dean-An Ling; Edward M Messing; Elizabeth Guancial
Journal:  Rare Tumors       Date:  2016-12-20

8.  A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets.

Authors:  Yepeng Li; Shiqing Huang; Zhongheng Wei; Bo Yang
Journal:  Oncol Lett       Date:  2020-03-27       Impact factor: 2.967

Review 9.  Chemotherapy for Lung Cancer in the Era of Personalized Medicine.

Authors:  Seung Hyeun Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-12-20

10.  Efficacy of relaxin for cisplatin-induced testicular dysfunction and epididymal spermatotoxicity.

Authors:  Tetsuya Kohsaka; Itaru Minagawa; Masashi Morimoto; Takuya Yoshida; Tomohiro Sasanami; Yoshitaka Yoneda; Naoki Ikegaya; Hiroshi Sasada
Journal:  Basic Clin Androl       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.